Roche to file MAA for eculizumab competitor
Roche AG has announced positive results from the non-blinded Phase III COMMODORE 1 and 2 trials at the EHA Hybrid Congress in Frankfurt, Germany.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1185 entries already.
Entries by Thomas Gabrielczyk
CGT Catapult expanding with Scotch facility
/in News/by Thomas GabrielczykThe world 3rd largest gene and cell therapy (CGT) cluster, the UK CGT Catapult has expanded its operations opening a subsidiary in Edinburgh.
Bayer AG is joining forces with Acuitas Therapeutics, Inc
/in News/by Thomas GabrielczykBayer boosts its gene therapy portfolio with lipid nanoparticle technology from Acuitas Therapeutics Inc.
Cytovation ASA raises US$8m in Series A
/in News/by Thomas GabrielczykBergen-based Cytovation ASA has raised US$8m in a Series A extension round to push its cancer compound CyPep-1 into Phase II clinical testing. ,
eXmoor Pharma Ltd raises US$35m
/in News/by Thomas GabrielczykBristol-based eXmoor Pharma Ltd has completed a US$35m Series A financing to expand its cell and gene therapy manufacturing capabilities.
Stem cell gene transfer treats IL-1 immune diseases
/in News/by Thomas GabrielczykItalian researchers have successfully ameliorated several IL-1-based autoimmune disorders by gene therapy into transplantable hematopoietic stem cells of mice.
Glioma drug combo turns tumours hot
/in News/by Thomas GabrielczykAn anti-TNF-antibody-cytokine fusion combo with chemotherapy turns inoperable brain tumours hot in mice. A Phase I trial sponsored by Philogen SpA is underway.
AI predicts an enzymes substrate
/in News/by Thomas GabrielczykA new machine learning model can predict enzyme-substrate pairs, with an accuracy of over 90% and is ready to be used in pharmaceutical and industrial biotechnology.
LanzaTech and Plastipak produce greener PET
/in News/by Thomas GabrielczykCarbon-capture specialist LanzaTech Global and Plastipak Packaging Inc have produced the worlds first PET resin made from captured carbon emissions.
Roches meets endpoints in relapsing multiple sclerosis
/in News/by Thomas GabrielczykRoche’s brutons tyrosine kinas blocker fenebrutinib has met all endpoints in proof-of-concept study with patients suffering from relapsing-remitting multiple sclerosis.